Find Clinical Trial

Phase I dose-escalation study of S 78454 (HDACi) p.o. in combination with FOLFOX in patients with locally advanced or metastatic digestive cancer


← Back
Study Phase

Phase 1

Therapeutic Area

Cancers

Active substance/
Medical device

ABEXINOSTAT, S078454

SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS078454
Protocol CodeCL1-78454-006
EudraCT Code2010-022369-89
ISRCTN CodeISRCTN75585722


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility